I was born on 6 August 1956 in San Francisco, California to Janet and (the late) Richard Hovis.
I grew up in Santa Monica, California where I attended elementary, junior high school, and high school (graduating in 1974), in addition to involvement in sports and recreation (Little League +, the Boy’s Club ++). Further, it was in elementary school – St. Augustine’s By-the -Sea Parish School that I found, and made the choice to truly journey with God.
I attended Arizona State University from 1974 to 1977 – seeking to become an architect, however, I was not accepted, and, as such, I graduated with a Liberal Arts degree.
Upon graduation from Arizona State University, I attended Cal Poly San Luis Obispo and studied City and Regional Planning at the Master’s level. I successfully completed one (1) year in a two (2) year program – I did not complete the Master’s degree in City and Regional Planning – due to personal reasons.
I returned to Santa Monica where I started (October 1979) my career as graphic designer with Exxon Company, USA. I spent five years with Exxon Company, USA.
While working with Exxon Company, USA I was accepted into architectural school – Sci-Arc in Southern California, however, I did not attend preferring to stay with Exxon..
In 1982 I married Laura Flosi and in April 1983 we had our one and only child – Lauren Alain Hovis – a gift from God.
We moved to Phoenix, Arizona in 1984 from Los Angeles, where I went to work as a graphic designer with Kitchell CEM (from 1985 -1987).
From 1987 – 1995 I was an independent contractor, and a registered representative in mortgage finance, financial management, graphic design, and drafting.
Further, I attended the University of Phoenix and successfully obtained a Master’s in Business Administration (MBA) in 1982.
I was also a member of the Scottsdale Jaycees, where I became very involved in community events and projects.
In 1994, I accepted a cartography position with the Defense Mapping Agency in Reston, Virginia. As such, I relocated from Phoenix to Reston.
In 1998, I was accepted and worked as a Visual Information Officer with the Central Intelligence Agency. In 2002, I worked as a Support Officer until my retirement (due to a need for shoulder surgery) in September 2018.
Away from my Federal Government service, I have been involved in various organizations and activities in Northern Virginia.
In November of 2011, I married Rebecca Ouellette in Santa Monica, California. I reside in San Tan Valley, AZ with my two hamster - Jess and Timothy, our fish, our lizard - RJ Lizard., and our cats - Pearl and Grey.
As to hobbies, I enjoy playing sports, attending sporting events, mentoring individuals from financial management to hamsters, building models, photography, travel, multimedia design, managing partner for RJ Hamster, and jazz – smooth jazz to a samba or a bossa nova.
Love and God Bless,
Peter – aka RJ Hamster Jo hi
DON’T MISS OUT: 10 Must-Do Non-Racing Activities at the Trans Am Memorial Day Classic
PHOTO STORY – Trans Am at Lime Rock Park, a Seven-Decade Photo Story
Memorial Day Classic
THIS WEEKEND!
THIS WEEKEND! Experience the thunder of 850-horsepower American V8s this Memorial Day with the TA and TA2 classes, while top production-based GT cars battle it out in XGT, SGT and GT!
Plus, don’t miss the thrilling sportscar action in International GT with late model Porsche and Ferrari competitors.
On Sunday, bring your Sunday Driver to the Royals’ Garage Car Show & see if you can take home bragging rights (& a trophy!) Entry proceeds will be donated to the Michael J. Fox Foundation for Parkinson’s Research.GET TICKETS – MEMORIAL DAY CLASSIC
Don’t Miss the Royals Garage Car Show This Sunday
For the 17th consecutive year, Royals’ Garage will wrap the track with amazing cars, all to benefit charity, rain or shine, on Sunday, May 24. This year’s event benefits the Michael J. Fox Foundation.
Show cars arrive between 8:00-11:00am, while gates open for spectators at 10:00am.
10 Must-Do Non-Racing Activities at the Trans Am Memorial Day Classic
Lime Rock Park is set to kick off its 69th season this weekend with the Trans Am Memorial Day Classic, but if the thunder of 850+ horsepower isn’t enough for you, we have five MUST-DO non-racing activities while you’re here, most of which are FREE with a General Admission ticket.
Trans Am at Lime Rock Park: A Seven-Decade Photo Story
Thirty-five years in the making, the Trans Am Series presented by Pirelli is set to return to Lime Rock Park. This Memorial Day weekend will mark the 35th Trans Am event at The Park. The Trans Am Memorial Day Classic returns to Lime Rock Park with SVRA and International GT May 21-24.
To celebrate the 35th Anniversary, here’s a look at some of Trans Am’s memories at Lime Rock Park over the last seven decades.CHECK OUT THE PHOTOS HERE
Welcome to The Pregame Lineup, a weekday newsletter that gets you up to speed on everything you need to know for today’s games, while catching you up on fun and interesting stories you might have missed. Today’s edition is brought to you by David Adler.
Jacob Misiorowski gets all the headlines. But the Brewers have a different breakout pitcher who’s looking like the steal of the offseason.
That’s Kyle Harrison, who has a 1.77 ERA and 59 strikeouts in 45 2/3 innings through nine starts for the first-place Brew Crew.
When Milwaukee traded for the 24-year-old left-hander from the Red Sox in February, Harrison was all upside. He was a former top prospect with the Giants, but he’d never really put it together in the big leagues.
Then he got into the Brewers’ pitching lab. Now Harrison looks like prime CC Sabathia. (CC is the only pitcher with a lower ERA than Harrison through his first nine starts as a Brewer.)
So how did Harrison become one of the best pitchers in the league out of nowhere? Here are three key changes he’s made with the Brewers:
1) His arm angle is higher
Harrison had a fairly low, almost sidearm delivery last season with the Giants and Red Sox. This year with the Brewers, he’s pitching out of a higher arm slot — as in, he’s throwing more over-the-top.
Harrison has raised his arm angle from 27 degrees in 2025 to 33 degrees in 2026. (Zero degrees would be perfectly sidearm; 90 degrees would be perfectly over-the-top.)
That might not seem like a huge increase, but it is the second-largest change among left-handed pitchers. Only Yusei Kikuchi has raised his arm angle more.
2) His fastball and slurve are sharper
Harrison relies mainly on his fastball-slurve combo — he throws those two pitches 87% of the time. And both of them are better this season.
The movement on both pitches has increased (this is likely a result of his arm angle change). Harrison has added close to three inches of “rising” movement on his four-seamer, and he’s added about an inch of drop and horizontal break to his slurve.
He’s also locating both pitches better. Harrison is commanding his fastball at the top of the zone, and he’s commanding his slurve at the bottom of the zone.
Last season, Harrison located just 24% of his heaters at the top edge of the strike zone or higher. This season, he’s throwing 44% of them in those elevated locations.
Meanwhile, Harrison’s frequency of locating his slurve at the bottom edge of the strike zone or below has jumped from 48% to 58%.
3) He’s changed his changeup
Harrison’s changeup is a clear third pitch behind his fastball and slurve, but that changeup is a new-and-improved version from what it was before.
Between 2025 and 2026, Harrison turned his normal changeup into a “kick change” — a trendy new version of a changeup that can help pitchers get extra movement from how they grip and release the pitch.
Harrison’s new kick change is getting an extra five inches of vertical drop in 2026 compared to what his old changeup was getting in 2025. That just gives him one extra weapon to get right-handed hitters out.
HOW AN ELITE SPEEDSTER GOT ELITE ON D, TOO
Chandler Simpson is one of the fastest players in the big leagues. You’d think that would make him great in the outfield, too, right? After all, most of the best defensive outfielders are elite speedsters — the Pete Crow-Armstrongs, Byron Buxtons and Billy Hamiltons of the world.
In theory, Simpson should be able to run down fly balls that other guys can’t. But as a rookie with the Rays last season, that theory did not translate into practice. At all.
Bizarrely, Simpson was one of the worstdefensive outfielders in the Majors, grading out at negative-5 Outs Above Average, according to Statcast. That combination of elite speed and poor outfield defense is highly unusual.
But this year, Simpson has flipped the script, tapped into his speed and become one of the league’s best defensive outfielders. He’s been worth +5 Outs Above Average — top-five in the Majors — and is making a huge impact for a red-hot Rays team that boasts MLB’s best record after its sixth sweep of the season.
A monster two-way Ohtani game, a pitchers’ duel between young stars and Skubal dialing up the heat highlight the action around the league.
• Two-way Shohei Ohtani is back and better than ever. Hitting and pitching in the same game for the first time since April 22, Ohtani belted a leadoff home run and threw five scoreless innings to beat the rival Padres. Ohtani has an .885 OPS as a hitter this season and a 0.73 ERA as a pitcher, the lowest in the Majors for anyone with at least 40 innings pitched.
• Trey Yesavage outdueled Cam Schlittler at Yankee Stadium in a pitching matchup between the two phenoms that lived up to the hype. The Blue Jays rookie tossed six scoreless innings with eight strikeouts, which was just enough to beat Schlittler, who finally blinked in the seventh inning when the Jays scratched out two runs against the Yankees’ young ace.
• Tarik Skubal’s speedy recovery from his “Skubal Scope” continues. The Tigers ace threw a multi-inning bullpen session today in Detroit, just two weeks after his surgery to remove a loose body from his left elbow. Skubal ramped up the velocity, too (not quite to game levels, but high-end velo for a bullpen). He said after: “There’s a velocity number I was trying to hit. And I hit it, so it was a good day.”
• D-backs ace Corbin Burnes is set to face live hitters for the first time since undergoing Tommy John surgery a little more than a year ago. The plan is still for Burnes, who has been throwing bullpen sessions for the past few months, to return around the All-Star break: “I should be right on time,” he said.
• The Braves are off to their best start through 50 games since 2003 after another dominant start by their ace, Chris Sale. Sale has a 1.89 ERA through his first 10 starts of the season, and Atlanta has the best record in the NL at 34-16.
ONE OF THE BEST FIRST YEARS EVER
A’s slugger Nick Kurtz, the reigning AL Rookie of the Year, completed his first 162 games in the big leagues earlier this week, the equivalent of one full season. And what he did over that “season” ranks among the best career-opening stretches of all time.
This is the stat line Kurtz posted over his first 162 career games:
.284 BA / .398 OBP / .581 SLG / .979 OPS
44 home runs
81 extra-base hits
107 walks
115 RBIs
119 runs scored
The 23-year-old is in historic territory with those numbers. Here are a couple of fun facts:
Kurtz’s 44 home runs are tied with Chuck Klein and Yordan Alvarez for the most by any left-handed hitter through his first 162 games.
Kurtz is one of just three lefties with at least 30 homers, 100 RBIs and 100 walks through 162 career games since RBIs became an official stat in 1920. The other two are Ted Williams and Juan Soto.
The only other hitters, righty or lefty, with at least 40 homers and 100 walks through their first 162 games are Aaron Judge and Rhys Hoskins.
Oh, and besides that heck of a first year, Kurtz is also riding an MLB-best 43-game on-base streak entering tonight’s game against the Angels (9:38 p.m. ET, MLB.TV). The A’s record is 48 games by Mark McGwire in 1996, and the MLB record is 84 games by Ted Williams in 1949.
PAGING DR. ROBBY
Calling all fans of “The Pitt” — the Pirates just announced the perfect giveaway for you.
The first 20,000 fans in attendance for the Pirates’ game vs. the Cubs on July 25 will get a one-of-a-kind bobblehead of Dr. Robby, the main character of the hit HBO Max medical drama.
The Dr. Robby bobblehead giveaway is part of “Yinzerpalooza Weekend” in Pittsburgh this summer.
Chris “CJ” Johnson, Lead Host & Senior Analyst, Monument Traders Alliance
Dear Reader,
There’s a chart I keep coming back to…
Not the price of the Dow…
Not new highs of the S&P 500 and Nasdaq…
This one:
And once you understand what it’s telling you, you won’t be able to ignore it either.
It’s called the $SPXA50R. It shows the percentage of S&P 500 stocks trading above their 50-day moving average.
Right now, that number sits at about 45%.
Let that sink in for a second.
The S&P 500 is near all-time highs. And yet fewer than half of its own stocks are trading above their 50-day moving average.
And while all the talking heads on CNBC are raving about record highs, I’m here to tell you the truth.
It’s not strength, it’s an illusion.
The 50-Day Is the Trend
I’ve been doing this for nearly 30 years, and the one thing that never goes out of style is the trend.
The 50-day moving average is the single cleanest way to measure it. When a stock is above its 50-day, it’s in a trend. When it’s below, it isn’t. Simple as that.
So, when I look at this chart and I see that only 45% of S&P 500 companies are above their 50-day MA, while the index itself is sitting at all-time highs, I proceed with extreme caution.
Because what that tells me is that a very small group of stocks is doing all the heavy lifting.
The rest of the index is barely treading water beneath the surface.
We’ve seen this movie before… it was called 2021 and early 2022.
The Magnificent 7 were carrying the entire index on their backs while the broader market was rolling over.
This chart looked nearly identical then. And you know what happened next…
Let’s look again at the five-year chart of the $SPXA50R. Pay attention to the middle stretch, the summer of 2022 through most of 2024.
That’s what you want to see.
Big, wide swings. Peaks and troughs of the indicator ripping from 5 or 10% all the way up to 90 or 95%, then pulling back, then doing it again.
That’s the rising tide lifting all ships.
When this indicator is swinging like that, it means capital is rotating broadly across the market. Sector after sector is participating.
That’s when traders make real money… both on the long and short side.
Because those deep valleys were some of the best buying opportunities of the last several years. And those peaks near 95% is when you tighten up, take profits, and start looking for the exits.
The Warning Sign
Now look at where we are today…
The indicator’s compressing, stuck in a tight range.
Just like the pattern we saw in early 2022, when this chart spent months unable to get above 40 or 45% before the market finally had its washout.
A tight chart like this means the market is being propped up by a handful of companies. The rest of the S&P is dead weight. And that’s a dangerous place to be, because there’s no clean way to play it.
You can’t trust the index. You can’t trust the breadth. You’re essentially trading on a handful of mega-cap names and hoping they don’t stumble.
That’s how traders lose 20 to 30% in a matter of months…
Not because they weren’t watching the S&P, but because they were watching only the S&P.
What to Do
Here’s how I’d approach it right now. Pull up a list of the S&P 500 companies that are above their 50-day moving average.
Those are the stocks doing the work. Those are your leaders.
Spoiler: it’s the usual suspects… Nvidia(NVDA), Apple (AAPL), Amazon(AMZN), Alphabet (GOOGL). These are the biggest stocks in the S&P, and they’re all well above their 50-day MA.
Then pull the reverse. Look up the biggest market cap names that are below their 50-day.
Home Depot (HD), Pepsi (PEP), Hershey (HSY), Target (TGT), etc… These are smaller names, sure. But there are much more of them below their 50-day MA.
These economically sensitive sectors reflect what’s really happening in the broader economy.
On the surface, the market’s headline number looks fine. But underneath it, the real economy is struggling to keep up.
And with shoulder season working against us (July, August, and September are historically the weakest months of the year) this compressed breadth could easily get amplified to the downside.
Keep an eye on this chart. It’s not flashy, and it doesn’t give you a buy or sell signal on a single stock…
But it will tell you whether this market has the foundation to sustain a rally… or whether it’s about to crack.
Right now, it’s telling me to be careful.Want more content like this?
You are receiving this email because you subscribed to Trade of the Day. To unsubscribe from Trade of the Day, click here.
Questions? Check out our FAQs. Trying to reach us? Contact us here. Please do not reply to this email as it goes to an unmonitored inbox.
To cancel by mail or for any other subscription issues, write us at: Trade of the Day | 14 West Mount Vernon Place | Baltimore, MD 21201 North America: 800.507.1399 | International: +1.443.353.4977 Website | Privacy Policy Keep the emails you value from falling into your spam folder. Whitelist Trade of the Day.
Nothing published by Monument Traders Alliance should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation.
Any investments recommended by Monument Traders Alliance should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company.
Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Monument Traders Alliance, LLC, 14 West Mount Vernon Place, Baltimore, MD 21201.
“The Yuma Proving Ground plays a vital role in America’s national defense and military readiness. This legislation ensures our service members can safely conduct advanced testing and training operations while protecting the long-term mission of one of the most important military installations in the country. Arizona is proud to support the men and women who defend our nation, and this bill strengthens that mission for decades to come.
“This is not a partisan issue. This is about military readiness, national security, and protecting the safety of the troops training at Yuma Proving Ground. Our military must have the tools, land, and operational flexibility necessary to prepare for modern threats and evolving battlefield conditions,” stated Congressman Gosar.
“I appreciate Mayor Nicholls’ testimony and his continued leadership in supporting Yuma’s defense community,” Gosar added. “His testimony reinforced that this legislation strikes the right balance between military readiness, responsible land management, public safety, and regional economic stability.”
During the hearing, Mayor Nicholls testified in strong support of the legislation, emphasizing the vital role Yuma Proving Ground plays in both America’s national defense and the regional economy. Mayor Nicholls described Yuma Proving Ground as “one of the most important economic engines in southwestern Arizona” and noted that the installation generates more than $1.1 billion annually in economic activity while supporting thousands of civilian and military jobs throughout the region.
Mayor Nicholls also stressed the public safety and military readiness benefits of the proposal, explaining that modern testing operations require “higher altitudes, greater offsets, and more complex tactical scenarios than the current land boundary can safely support.” He further testified that expanding the withdrawal area to Highway 95 would improve public safety by creating a clear and visible boundary while allowing the Army to safely conduct advanced air delivery testing critical to future military operations.
Background:
Congressman Gosar introduced H.R. 8686 on May 8, 2026. The bill authorizes the withdrawal of approximately 21,783 acres adjacent to Highway 95 to establish a larger safety buffer zone for military air delivery system testing. According to Army analysis, the additional land is necessary to support higher-altitude testing, longer glide distances for guided parachute systems, and more advanced tactical training scenarios that cannot safely occur under current land limitations.
The legislation also formally withdraws and reserves approximately 249 acres within the Howard Cantonment area that has been continuously utilized by the Army since 1955 under authorities that have since expired.
Importantly, the proposal originated during the Biden Administration and underwent environmental review and interagency approval before ultimately receiving formal approval under the Trump Administration, underscoring the nonpartisan nature of the military’s operational need.
Click here to watch my questions directed to Mayor Nicholls.
Health, finance & everyday support – all in one place
Hand-Picked Story (ad)
Caught on Camera: Trump’s Robot Dog Spotted at Mar-a-Lago (Behind the Markets) Editor’s Note: Former tech executive and angel investor Jeff Brown — picked Bitcoin before it jumped as high as 52,400%, Tesla before it jumped as high as 2,150%, and Nvidia before it jumped as high as 32,000%. Today, he’ll show you how to claim a stake in Elon Musk’s upcoming IPO — BEFORE the company goes public.Click here to see the details or read more below.
Last week, while the world watched Artemis and tracked tensions with Iran…
Elon Musk’s team quietly filed paperwork with the SEC.
Jeff Brown Founder & CEO, Brownstone Research TODAY’S BONUS ARTICLE
Ancient Rocks Beneath Canada Are Producing Hydrogen at Massive Scale. A Drug Just Reversed Skin Aging and Tripled Wound Healing Speed. And People Who Lose Weight on Ozempic Face More Social Judgment — Not Less.
A clean energy discovery that could change the hydrogen economy, a dermatology breakthrough that reverses cellular aging in skin, and an unexpected social science finding about GLP-1 drugs.
Ancient Rocks Beneath Canada Are Naturally Producing Hydrogen — at a Scale That Surprised Scientists
Scientists in Canada discovered that ancient underground rock formations — specifically precambrian shield rocks billions of years old — are naturally generating hydrogen gas through a geological process called serpentinization, in which water reacts with iron-bearing minerals deep underground. The scale of production was described as massive and unexpected. The discovery adds Canada to a growing list of locations — including Mali, Oman, and parts of the U.S. — where naturally occurring geological hydrogen has been identified.
Why this matters: hydrogen is considered one of the most promising clean energy carriers, but producing it industrially is expensive and energy-intensive. Natural geological hydrogen — sometimes called “gold hydrogen” — would be far cheaper to extract if it can be accessed at sufficient scale. Several startups are already drilling for it in Mali and the U.S. Midwest. If Canadian reserves prove commercially viable, they would represent a significant addition to the global clean energy supply chain — particularly for industrial processes that are hard to electrify.
The discovery is early-stage in terms of commercial extraction — the scale of the resource doesn’t automatically translate to extractable supply. But the pattern of geological hydrogen discoveries accelerating globally over the past three years is becoming hard to ignore. It’s being watched closely by energy companies and investors who have been skeptical of hydrogen’s commercial future.
A Drug Just Reversed Skin Aging and Tripled the Speed of Wound Healing in Older Tissue
Scientists discovered that a topical drug called ABT-263 — originally developed as a cancer treatment — can dramatically improve wound healing in older skin by removing the senescent “zombie cells” that accumulate with age and impair the skin’s ability to repair itself. In experimental testing, treated older skin showed wound healing speeds roughly three times faster than untreated aged skin, and the treated tissue exhibited markers more consistent with younger skin in terms of collagen production and cellular regeneration.
Wound healing in older adults is a significant medical challenge. Chronic wounds and slow-healing injuries are a leading cause of hospitalization, amputation, and infection-related complications in people over 65. Standard of care has changed little in decades. A drug that clears the cellular debris that blocks healing — rather than just managing the wound surface — represents a mechanistically different approach. ABT-263 is being studied for topical use, which would localize its effects and minimize the systemic risks associated with senolytic drugs when taken systemically.
This connects to the broader senolytic research field — the same category as the Mayo Clinic aptamer work published last week. Clearing senescent cells from aged tissue is emerging as one of the most consistent approaches to reversing localized aging effects. The skin represents one of the most accessible tissues for this kind of intervention.
People Who Lose Weight on Ozempic Face More Social Judgment — Not Less
New research found a counterintuitive social dynamic around GLP-1 weight-loss drugs: people who lose weight using Ozempic or Wegovy may actually face more social judgment than those who lose weight through diet and exercise — or even those who don’t lose weight at all. The stigma appears rooted in a widely held perception that drug-assisted weight loss is somehow less legitimate or less deserved than behavioral change.
The research is notable because it runs counter to the assumption that results speak for themselves. Effective weight loss through any means tends to improve how others perceive someone — but the medication route appears to activate a specific bias around effort and merit that offsets the social benefit of the physical change. This reflects a broader cultural pattern in which the methods used to achieve health outcomes are morally weighted in ways that have no basis in biology.
The practical reality: obesity is a complex metabolic condition with strong genetic and hormonal components. GLP-1 drugs work by addressing biological mechanisms — not by substituting for willpower. The social judgment documented in this research reflects a misunderstanding of how these drugs work and why they’re needed, and it adds a meaningful barrier to people seeking effective treatment for a condition that significantly affects health outcomes.
Also Today→ Nvidia $81.6B — beat by $3B, Q2 guided above $87B consensus — dividend raised 20x from $0.01 to $0.20/share. Free cash flow hit $49B. S&P and Nasdaq opening higher this morning→ Hidden Alzheimer’s trigger identified and disabled — enzyme IDOL, when removed from neurons, sharply reduced amyloid plaques in experimental models. New drug target identified→ Home Depot reports today — after Walmart’s strong results yesterday, the home improvement data tells whether Americans are still investing in their homes or pulling back→ DNA from poop is being used to track and protect one of the world’s rarest marsupials — fewer than 150 Gilbert’s potoroos remain in Australia. Genetic monitoring from fecal samples is tracking individual animals without capture
RJ the hamster and producer Mina guide you through a fast, funny morning show full of practical pep: Morning Nibble News, a bite-sized motivational speech about small wins, a playful “Breakfast Court” ruling, and listener questions about snooze, overwhelm, and energy. Expect simple, doable tips—make your bed, drink water, set your alarm across the room—and one clear challenge to make your future self grateful.
Lighthearted, warm, and actionable, this episode helps you start the day without self-judgment: pick one important thing, shrink the to-do list into three items, and take the next right step. Tiny, steady moves—hamster-approved.
At Bible Study Tools, we’re dedicated to helping you grow in God’s Word. Along with your Bible Tools Collection, here are more resources to deepen your study time:
This email is never sent unsolicited. You are receiving this email because your email address, peterhovis@icloud.com, is signed up to receive newsletters, updates, and special offers from BibleStudyTools.
Shares of Eli Lilly and Company (NYSE: LLY), the world’s most valuable pharmaceutical stock, started 2026 in a bad way. Near the end of April, LLY shares had fallen as much as 20%. However, the stock has rebounded mightily since then.
Lilly’s highly impressive earnings report kicked off the rally, with shares surging nearly 10% in one day. Lilly has continued to trudge higher, now down only around 5% in 2026.
One event that recently helped Lilly’s stock move up was the latest results surrounding its oral GLP-1 medication Foundayo. While Foundayo is already approved by the Food and Drug Administration, the need to continue testing does not stop there. By generating more robust and a wider variety of data on the medication, Lilly can improve the chances of doctors prescribing it. Lilly’s latest results support this all-important goal.
Foundayo’s 2-Pronged Attack: Needle Fear Patients and Maintenance Patients
The trial in question focuses on weight-loss maintenance—helping patients keep lost weight off after they stop taking high-dose GLP-1s. For Lilly, this is part of a two-pronged strategy to generate demand for Foundayo.
The first part is based on attracting completely new patients. Researchers estimate that up to 25% of U.S. adultshave a fear of needles, preventing certain patients who want to lose weight from taking injectable GLP-1s. Through pill-based medications, Lilly can unlock demand from this patient group.
However, Lilly is falling behind Novo Nordisk A/S (NYSE: NVO) on oral uptake, as Novo received approval for its oral weight-loss drug several months earlier. Novo’s pill has also demonstrated efficacy that moderately surpasses Foundayo. Novo notes an average weight loss of 14% after 64 weeks among patients taking the Wegovy pill. This compares to an average weight loss of 12.4% after 72 weeks for Foundayo.
According to BMO Capital Markets, “While Foundayo scripts have been trending upward since launch in April, scripts have lagged vs. those of the Wegovy Pill and Street expectations.”
However, Lilly may be able to better differentiate itself in the second prong of its strategy: weight loss maintenance. Injectables are more efficacious than either pill, with Lilly touting an average weight loss of 20.2% at 72 weeks for patients using Zepbound. Thus, after losing a lot of weight on injectables, patients can transition to pills in order to keep lost weight off.
With this, Lilly can drive recurring sales of Foundayo as patients make the switch. Its latest Foundayo results provided encouraging data on this front.
Foundayo: Weight Loss Maintenance Improves Dramatically Versus Going Cold Turkey
In its ATTAIN-MAINTAIN trial, Lilly looked at patients who had lost significant weight through taking Zepbound. Throughout the Zepbound period, patients lost an average of 55 lbs. Patients then transitioned onto Foundayo for 52 weeks, gaining back 11 lbs. So, when using Foundayo as a maintenance treatment, patients regained only 20% of their original weight loss.
This is actually a strong showing, as patients who get off GLP-1s completely regain much more weight. A recent analysis of 48 studies found that after one year of getting off GLP-1s, patients regained 60% of their original weight loss. Thus, the percentage of weight loss kept in Lilly’s study is three times higher than that of those who got off GLP-1s completely.
Lilly also performed the same test with patients who originally lost 41 lbs by taking injectable Wegovy. After switching to Foundayo for 52 weeks, these patients regained just 2 lbs—another very strong result. In the end, Zepbound to Foundayo patients lost 17.2% of their weight, and Wegovy to Foundayo patients lost 15.5% of their weight on average.
Clearly, these results provide evidence that transitioning to Foundayo after taking injectables can be an effective pathway for keeping lost weight off. Notably, on the day of this data release, Lilly’s shares rose by 2.4%.
There is also reason to believe that Foundayo will have greater appeal as a weight-loss maintenance treatment than the Wegovy pill. This is because it comes with no dietary restrictions. Meanwhile, doctors advise Wegovy pill patients not to eat or drink for 30 minutes after taking the medication.
Ultimately, the convenience factor of pills is a key reason why people would want to switch from injectables. With no dietary restrictions, Lilly has an advantage here. However, it will be interesting to see if Novo conducts a similar maintenance study that could shift the playing field in this vertical.
Analysts Forecast Substantial Upside in Lilly After Recent Rebound
Overall, targeting the weight-loss maintenance market is one of many levers Eli Lilly can pull to continue growing its GLP-1 business. Notably, even with Lilly only down less than 10% from its all-time high, Wall Street analysts continue to forecast substantial gains ahead. The MarketBeat consensus price target on the stock sits near $1,218, implying upside of just over 20%. READ THIS STORY ONLINE
$1 quadrillion would be enough to send a $2.8 million check to every man, woman, and child in America. That is the scale of what analysts are calling the biggest AI IPO in history.
And right now, you can claim a stake before the company goes public, starting with just $500.
Elon Musk is predicting this investment could climb 1,000x from here. Early access is available today. CLAIM YOUR STAKE NOW
The artificial intelligenceinfrastructure buildout is entering its consolidation phase. In a decisive move that reshapes the competitive landscape, private equity giant Blackstone (NYSE: BX) and hyperscaler Alphabet (NASDAQ: GOOGL) announced a $5 billion joint venture to create a new AI cloud platform. This alliance directly targets the operational moats of high-flying, pure-play infrastructure providers, signaling a fundamental market rotation toward mega-cap players with unmatched access to capital.
For investors, this catalyst clarifies the board. The era of speculative premiums for companies with GPU capacity appears to be closing, replaced by a new reality in which balance sheet strength and cost of capital are paramount. This shift creates a compelling opportunity for a classic pairs trade, favoring the unlevered scale of institutional giants over the debt-fueled growth of their mid-tier rivals.
Forging a Debt-Free Weapon With Capital and Silicon
The partnership between Blackstone and Google is more than just another data center deal; it’s a vertically integrated assault on the AI compute market. Blackstone is making an initial $5 billion equity commitment to bring 500 megawatts of capacity online by 2027, with plans to scale significantly. The new, U.S.-based entity will offer Google’s proprietary Tensor Processing Units (TPUs) as a compute-as-a-service offering.
The deal structure presents two immediate and formidable advantages. First, by using pure equity, the venture completely bypasses the increasingly expensive debt markets that competitors rely on for expansion, creating a superior unit economics model from its inception.
Second, it fuses Blackstone’s global expertise in real estate, energy, and digital infrastructure with Google’s decade-plus of experience developing and deploying its custom-built AI accelerators. TPUs already power Google’s entire suite of AI products, including Gemini, giving the new platform a foundation of proven, at-scale technology. This combination of deep private equity backing and proprietary hardware presents a structural challenge to the existing pure-play AI cloud operators.
Caught in the Crossfire: The Squeeze on Levered Operators
While the AI boom has lifted many boats, the tide may be turning for operators whose growth is built on significant debt. The entrance of a debt-free, institutionally backed competitor puts a magnifying glass on the financial structures of these mid-tier players.
CoreWeave’s High-Wire Act
CoreWeave (NASDAQ: CRWV) has been a primary beneficiary of the market’s insatiable demand for GPU capacity. However, its aggressive expansion has come at a cost.
CoreWeave operates with a substantial debt-to-equity ratio of 3.68, financing its growth at borrowing rates reportedly exceeding 9%. This heavy reliance on leverage creates significant margin compression. In a market where a new competitor can deploy billions in equity, CoreWeave’s high cost of capital may become a critical vulnerability. The negative net margin of -25.57% and return on assets of -3.84% at CoreWeave underscore the immense capital intensity of its operating model, which now faces a direct challenge from a far more efficiently capitalized rival.
Nebius Group’s Sales Multiple in the Firing Line
Another market favorite, Nebius Group (NASDAQ: NBIS), faces a different kind of pressure. While its financial footing is more stable, its valuation appears priced beyond perfection.
Nebius Group trades at a staggering 93 times its annual sales. This kind of multiple leaves zero room for error and assumes a long-term growth trajectory with no significant competitive threats. The Blackstone-Google venture fundamentally invalidates that assumption. With a -9.11% return on equity, Nebius Group’s current market capitalization of over $50 billion is difficult to justify on fundamentals alone. The arrival of a new, powerful competitor makes Nebius Group’s forward guidance look far more precarious, placing its premium valuation at high risk of a substantial correction.
Downgrades, Dumps, and Derivatives
Wall Street appears to be recognizing this structural shift. In the wake of the joint venture announcement, DA Davidson downgraded both CoreWeave and Nebius Group. The CoreWeave downgrade centered on concerns over its thin margins and rising input costs, while the Nebius Group downgradepointed to a valuation that had reached a saturation point.
This cautious analyst sentiment is echoed by insider activity. Recent filings show notable stock sales by key executives at CoreWeave and Nebius Group. While insider selling can happen for many reasons, the timing suggests a potential recognition that the competitive environment is becoming materially more difficult.
Derivatives markets are showing signs of institutional hedging, with rising implied volatility and skewed put-to-call ratios on near-term options contracts for these pure-play operators. This activity indicates that sophisticated investors may be actively purchasing downside protection.
Playing Offense and Defense in the AI Shakeout
The data points to a clear and actionable thesis. The AI infrastructure sector is consolidating, and the advantage is shifting decisively toward large, vertically integrated players with pristine balance sheets. Recent geopolitical news has triggered broad market selloffs, but this has masked the underlying capital flight from highly levered operators toward fortified mega-caps.
For investors with a strategic, long-term view, this environment may be well-suited for a pairs trade. Such a strategy would involve a bullish position on a hyperscaler like Alphabet, which stands to benefit directly from this consolidation, while taking a bearish position on capital-intensive pure-plays like CoreWeave or the richly valued Nebius Group.
Investors should, of course, consider the risks. The sheer scale of demand for AI compute could create opportunities for all players in the short term. The Blackstone-Google capacity is not scheduled to come online until 2027, giving incumbents a window to strengthen their positions. Mid-tier operators could also become attractive acquisition targets for other tech giants looking to accelerate their entry into the AI infrastructure space.
Still, the catalyst is clear. The injection of $5 billion of unlevered private equity into the AI cloud war has permanently altered the rules of engagement. Investors focused on this space might consider re-evaluating their exposure to operators reliant on expensive debt, while closely monitoring the execution of hyperscaler alliances as a key indicator of where the market is heading. READ THIS STORY ONLINE
Most traders do not lose because they are unlucky – they lose because they are late. Chasing moves that have already run, hesitating at key moments, or overcomplicating entries until the opportunity is gone.
Dave Aquino, Lead Income Trader at Base Camp Trading, built his single-day trading approach around pre-defined setups, specific timing windows, and clear decision points – so you are anticipating moves instead of reacting to them. His free report breaks it all down.CLAIM YOUR FREE COPY OF DAVE AQUINO’S SINGLE-DAY TRADING REPORT
This is a pressing issue, as permanent magnets are essential to building many modern-day technologies. This includes advanced weaponry, and the United States does not want to find itself in a position where China can cut off its production capabilities.
Ultimately, the goal of USA Rare Earth is to become a vertically integrated mine-to-magnet producer. Recently, USA Rare Earth delivered its latest earnings report, providing insight into how the firm is progressing toward its goal.
USA Rare Earth Posts Beats, Government Funding Deal Sees a Delay
As an early-stage company, showing operational improvements is far more important than near-term revenue or profit generation. However, that’s not to say the company’s financials don’t matter at all—investors certainly want to see it stay on budget and not burn cash unnecessarily. Luckily, in its latest quarter, the firm posted better-than-expected results.
USA Rare Earth generated revenue of $5.7 million in Q1 2026. Note that it recorded no revenue a year ago. This figure solidly beat estimates of $4.2 million. The company also exceeded expectations on its bottom line. The company’s adjusted loss per share was 12 cents, significantly less than the 16-cent loss analysts had forecasted.
However, it is important to note that loss per share can be a deceiving metric. Because USA Rare Earth issues a lot of stock, its loss per share can fall even if actual losses grow, which is exactly what happened during Q1. Adjusted loss per share improved from 14 cents a year ago, but the company’s adjusted net loss more than doubled to $24.1 million. The takeaway is that USA Rare Earth’s profitability is getting worse, not better.
However, this is fully expected for early-stage companies, and USA Rare Earth has plenty of capital to absorb losses. The firm ended the quarter with $1.75 billion in cash, as it received $1.5 billion in proceeds from a private investment offering.
Additionally, the company said it expects to complete the definitive documentation for its $1.6 billion in Department of Commerce funding in May. While a delay compared to previous expectations that this would finish up in April, ultimately getting the funding is what matters. Importantly, the firm notes that the terms of the deal have not deteriorated.
USA Rare Earth Presses Forward, Looks to Enhance Position With Serra Verde
The company also remained on course with several operational milestones. The company continues to expect to begin fulfilling sales of sintered magnets in Q2 2026.
USA Rare Earth also still expects its Stillwater magnet capacity to hit 600 metric tons per annum (MTPA) by the end of 2026. Expectations for 1,200 MTPA in Q1 2027 remain intact as well.
However, its planned $2.8 billion acquisition of Serra Verde is by far the biggest development over recent months. The company notes that Serra Verde is the first and only scaled producer of all four magnetic rare earth elements outside of Asia. These elements are neodymium (Nd), praseodymium (Pr), dysprosium (Dy), and terbium (Tb).
Garnering this asset would be a clear win for USA Rare Earth, accelerating its mine-to-magnet buildout and providing a key benefit compared to MP Materials. MP’s mines are rich in only light rare earth elements like Nd and Pr—not heavy rare earths like Dy and Tb. Notably, making advanced technologies like missile guidance systems requires adding heavy rare earths. With Serra Verde, USA Rare Earth would have access to both light and heavy REEs, a strategic advantage over MP.
The combined company is targeting an EBITDA run rate of $550 million to $650 million by the end of 2027. Additionally, USA Rare Earth notes that the cash position of the combined firm would be $3.2 billion, drastically higher than its current balance.
However, the acquisition is set to be a massively dilutive event for shareholders. USA Rare Earth plans to issue 127 million shares to fund the deal. This is huge compared to its current share count of nearly 233 million. Nonetheless, shares surged 13% on the day of this announcement, indicating that investors prioritized the strategic value of the deal over the dilution factor.
USA Rare Earth Awaits Deal Closing After Good Quarter
Overall, USA Rare Earth performed well during its latest quarter, putting up solid financials and continuing to execute on operational objectives. Meanwhile, it’s possible that acquiring Serra Verde could be a game-changer—making the company an anchor in the non-China market.
Still, the deal has yet to close, with finalization expected in Q3 2025. After closing, USA Rare Earth plans to host its Investor Day. As the company provides more details around its strategy at the event, this will be a key point at which to re-evaluate USAR’s future. READ THIS STORY ONLINE
Elon Musk’s AI lab has partnered with the Department of Defense, Oracle, and Palantir – and he just filed confidential IPO paperwork. By the time it goes public, most investors will have missed the biggest gains.
Louis Navellier, a 47-year Wall Street veteran who has recommended over 675 stocks that climbed 100% or more, says he’s found a way to profit ahead of the IPO. He’s backed his conviction with $358 million of his own firm’s money. Goldman Sachs projects the underlying technology could surge 70X over the next decade.SEE NAVELLIER’S FULL ANALYSIS AND HOW TO POSITION TODAY
The Night Owl is a financial newsletter that provides in-depth market analysis on stocks of interest to individual investors. Published by MarketBeat and Early Bird Publishing, The Night Owl is delivered around 9:00 PM Eastern Sunday through Thursday. If you give a hoot about the market, The Night Owl is the newsletter for you.
(By clicking the link above, you agree to receive emails from Marketbeat. You can opt out at any time. – Privacy Policy)
Banking
Goldman Sachs Wants More of the Money Behind Global Trade
Goldman Sachs (NYSE: GS) is expanding its presence in private credit with the acquisition of FGI Worldwide. The company provides working capital finance, receivables funding, and trade credit insurance for businesses across more than 60 countries.
Goldman Gets Closer to Everyday Business Cash Flow
FGI helps companies access money tied up in invoices, receivables, and cross-border operations. That may not sound flashy, but it is the plumbing that keeps businesses moving.
When you strip away the Wall Street noise, this deal puts Goldman Sachs closer to companies that need flexible financing. It is not about stock charts; it is about keeping business wheels turning.
Private Credit Is the Bigger Prize
Goldman Sachs Alternatives is adding a platform that already works with small and medium-sized businesses.
That gives the firm a stronger position in a market where companies increasingly look beyond traditional bank loans.
The timing makes sense. Supply chain pressure, tighter credit, and global uncertainty make flexible financing more important.
Your average business owner may not care who owns the platform, but they care when cash flow gets tight.
A Smarter Expansion Move
FGI also brings technology and underwriting experience. That gives Goldman a business it can scale rather than building from scratch.
For you, the bigger takeaway is simple. Goldman Sachs is not just chasing big deals at the top of finance; it is moving deeper into the practical money needs of businesses worldwide.
GS currently trades at $961 and pays a dividend of $18.00 per share, a yield of 1.87%.
Beverages
PepsiCo’s Functional Drink Push Just Got More Serious
PepsiCo (NASDAQ: PEP) is giving its Propel brand a bigger job. The company has introduced Propel Clear Protein, a beverage powder with protein, fiber, and electrolytes in one drink.
Propel has long lived in the hydration lane. Now PepsiCo is pushing it into the functional beverage space, where shoppers want drinks that do more than taste good.
When you see a brand move from hydration into protein and fiber, it shows where consumer demand is heading.
People want simple wellness products without feeling like they are drinking a chalky gym locker room.
Protein Meets Convenience
Each serving has 20 grams of whey protein and 3 grams of fiber. The powder comes in peach ginger, apple pear, and watermelon.
That matters because PepsiCo is not building a niche fitness product. It is turning Propel into a more everyday option for busy consumers who want hydration and nutrition in one quick mix.
A Bigger Wellness Play
PepsiCo is already a giant in snacks and drinks. Products like this help the company stay relevant as health-focused shoppers keep changing the rules.
If Propel Clear Protein works, PepsiCo gets more than another powder. It gets a bigger wellness platform that can stretch into protein, hydration, fiber, and everyday nutrition.
That helps the company stay relevant as shoppers move toward drinks that do more than refresh.
PEP currently trades at $150 and pays a dividend of $5.69 per share, a yield of 3.79%.
First users could have already grown their money dramatically every single year this AI has been running, based on the average winning trades it uncovers – WITHOUT following market news, WITHOUT watching central banks, and WITHOUT the stress most traders deal with daily.
Nike (NYSE: NKE) is launching a new AI-powered shopping feature that lets U.S. customers discover and buy products directly through Google’s Gemini app and AI Mode in Search. The feature rolls out in early June.
AI Becomes the New Storefront
Nike is not just adding another online checkout button. It is moving closer to shoppers at the exact moment they search, compare, and decide what to buy.
When you ask AI for product help, Nike wants to be right there with the answer and the purchase option. That could make discovery feel less like browsing and more like instant buying.
Nike Keeps the Customer Link
The feature uses Google’s shopping system and stored payment details to speed up checkout. Nike still keeps the consumer relationship, which matters a lot.
That balance is important for your read on the company. Nike gets access to Google’s AI shopping flow without giving up the direct connection it has spent years building.
AI Search Becomes the New Storefront
Nike’s website turns 30 this year, but the company is not treating digital retail like old furniture. Apps, SNKRS, marketplaces, Gemini, and AI Mode are all part of the same push.
If this works, Nike gets a new sales channel inside the place where shoppers already search, compare, and decide.
You may no longer need to start in a shopping app, because Nike wants the buying moment to happen within AI search.
NKE currently trades at $44 and pays a dividend of $1.64 per share, a yield of 3.81%.
Dividend Stocks Worth Watching
The Wendy’s Company (NASDAQ: WEN) has appointed restaurant industry veteran Robert Wright as its new CEO amid falling sales, restaurant closures, and renewed speculation about activist investor involvement.
What stands out here is the timing.
Wendy’s is bringing back an executive with deep experience across major restaurant brands just as the company faces mounting pressure to stabilize traffic and reconnect with inflation-weary consumers.
The leadership change also comes amid reports that Nelson Peltz’s Trian Fund Management is exploring a move to take the company private.
The operational challenges are significant.
Same-store sales have weakened sharply, hundreds of underperforming US locations are being closed, and management has admitted the company leaned too heavily on short-term promotions rather than building stronger everyday value.
Wendy’s is now trying to reset its positioning while modernizing an aging store base.
For dividend investors, this is shaping up to be a turnaround-and-restructuring story. A more experienced leadership team and potential strategic pressure from activist investors could accelerate change.
However, the company still needs to prove it can rebuild customer demand and improve execution in a highly competitive fast-food market.
WEN pays a 14-cent quarterly dividend, yielding 6.98%.
Stellantis N.V. (NYSE: STLA) and Great Britain’s Jaguar Land Rover have signed an agreement to explore collaboration opportunities in the US market, focusing on product and technology development.
What makes this interesting is that it reflects how rapidly the automotive industry is moving toward partnerships and shared development.
Automakers are facing rising costs tied to electrification, software, regulation, and manufacturing, making it increasingly difficult to fund future growth on their own.
Collaborations like this allow companies to spread costs, accelerate development, and strengthen their competitive position without pursuing full mergers.
For Stellantis, the agreement also reinforces a broader strategic shift toward alliances.
The company has already been expanding partnerships in electric vehicles and related technology, particularly as competition intensifies from both traditional rivals and Chinese EV manufacturers.
For dividend investors, this is another sign that scale and collaboration are becoming essential in the next phase of the auto industry.
The long-term opportunity depends on whether Stellantis can use these partnerships to improve efficiency, strengthen innovation, and protect profitability during a difficult transition period for global carmakers.
STLA pays a 68-cent annual dividend, yielding 10.29%.
Target Corporation (NYSE: TGT) has delivered its strongest comparable sales growth in four years, suggesting the retailer’s turnaround strategy under new CEO Michael Fiddelke is gaining traction.
What makes this especially notable is the breadth of the recovery.
Sales improved across all major merchandising categories, reversing several quarters of declines and giving management enough confidence to raise full-year revenue guidance.
The company is also seeing signs that investments in stores, staffing, and product assortment are starting to reconnect with shoppers.
For dividend investors, this is shaping into a genuine recovery story rather than a short-term bounce. Target is trying to rebuild traffic, restore brand momentum, and regain market share in key categories like home and apparel.
If management can sustain the current sales momentum while improving profitability, the turnaround could start looking much more durable.
TGT pays a $1.14 dividend, yielding 3.75%.
Dividend Increases
NOC has boosted its dividend to $2.47, up 6.93%. Its new yield is 1.78%.
UVV has increased its dividend to 83 cents, up 1.22%. Its new yield is 6.1%.
FRME has raised its dividend to 37 cents, an increase of 2.78%. Its new yield is 3.74%.
HNI has increased its dividend to 35 cents, a 2.94% increase. Its new yield is 4.63%.
Dividend Decreases
PDCC has reduced its dividend to 13 cents, a 40.91% cut. Its new yield is 14.61%.
America’s largest banks have quietly pulled in massive returns for years — while everyday savers are left with scraps.
Now, one income strategist reveals a little-known investment that has historically delivered far higher long-term returns — and it may be accessible to regular investors.
C’s ex-dividend date for the forthcoming 60-cent payment is 05/22/26.
CARR’s ex-dividend date for the forthcoming 24-cent payment is 05/22/26.
FAST’s ex-dividend date for the forthcoming 24-cent payment is 05/26/26.
CAKE’s ex-dividend date for the forthcoming 30-cent payment is 05/26/26.
Everything Else
A free report identifies the 10 stocks built to surge first when the Fed begins cutting rates this cycle.
Mark Zuckerberg says he doesn’t expect to make any more job cuts in 2026, after cutting its workforce by 10%.
Hasbro has teamed up with Formula 1 to launch a new version of the popular board game Monopoly. The new theme game is based on the 2026 race teams and locations.
Bristol-Myers Squibb is expanding its adoption of Claude, with the pharma giant saying it plans to lean heavily on AI to accelerate software development and R&D.
That’s all for today’s edition of the Dividend Brief.
Thanks for reading, and if you have any feedback or dividend stocks you want me to take a look at, just reply to this email!
—Noah Zelvis DividendBrief.com
Legal Stuff: Stocks featured in this newsletter are for entertainment purposes only. You should not base any investment decisions on information contained in my newsletter. Stocks featured in this newsletter may be owned by owners/operators of this website, which could impact our ability to remain unbiased. Please consult a financial advisor before making any trading decisions. I may earn a small commission from links placed inside these emails.
You are receiving this e-mail because you are a subscriber to Chaikin Analytics content. To unsubscribe from special offers like this one, click here to unsubscribe.
Published by Chaikin Analytics, LLC.
You’re receiving this e-mail at pahovis@aol.com. For questions about your account or to speak with customer service, call +1 (877) 697-6783 (U.S.), 9 a.m. – 5 p.m. Eastern time or e-mail info@chaikinanalytics.com. Please note: The law prohibits us from giving personalized financial advice.
RJ Hamster 